Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study

Shriram M. Pathak, Prashant B. Musmade, Krishnamurthy M. Bhat, Nayanabhirama Udupa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: A simple HPLC-UV method with a high reproducibility and sensitivity for the determination of talinolol in rat plasma was developed in this study. Method: After liquid-liquid extraction, the compounds were separated on a Vydac® C18 monomeric column (250 × - 4.6 mm inner diameter × - 5-μm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min-1. Escitalopram was used as an internal standard. The chromatographic peak-area ratio, based on UV absorbency at 245 nm, was used for quantitative analysis. Results: Calibration standards with concentrations over the range of 10-1000 ng ml-1 were validated for routine sample analysis to support pharmacokinetic studies with talinolol in rats. The intra- and inter-day precision studies showed good reproducibility with coefficients of variation of less than 11.49%. The developed method is simpler and more sensitive than previously reported methods. Discussion: The analytical sensitivity and accuracy of this assay were adequate for characterization of talinolol in rat plasma and the assay has been applied successfully to the in vivo kinetic study of talinolol in rats. After talinolol (10 mg kg-1) was given orally, the maximum concentration and the AUC0-∞ were 341.8 ± 99.4 ng ml-1 and 976.26 ± 173.37 ng h ml-1, respectively. The oral bioavailability was approximately 52.14 ± 9.26%. Conclusion: The advantages of our method are a small sample volume (200 μl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.

Original languageEnglish
Pages (from-to)95-104
Number of pages10
JournalBioanalysis
Volume2
Issue number1
DOIs
Publication statusPublished - 01-2010

Fingerprint

talinolol
Pharmacokinetics
Rats
High Pressure Liquid Chromatography
Plasmas
Assays
Citalopram
Liquids
Liquid-Liquid Extraction
Washing
Buffers
Particle Size
Calibration
Biological Availability
Particle size
Flow rate

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Clinical Biochemistry
  • Medical Laboratory Technology

Cite this

@article{c9a7db170004471aa6032c7077d61a1f,
title = "Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study",
abstract = "Background: A simple HPLC-UV method with a high reproducibility and sensitivity for the determination of talinolol in rat plasma was developed in this study. Method: After liquid-liquid extraction, the compounds were separated on a Vydac{\circledR} C18 monomeric column (250 × - 4.6 mm inner diameter × - 5-μm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min-1. Escitalopram was used as an internal standard. The chromatographic peak-area ratio, based on UV absorbency at 245 nm, was used for quantitative analysis. Results: Calibration standards with concentrations over the range of 10-1000 ng ml-1 were validated for routine sample analysis to support pharmacokinetic studies with talinolol in rats. The intra- and inter-day precision studies showed good reproducibility with coefficients of variation of less than 11.49{\%}. The developed method is simpler and more sensitive than previously reported methods. Discussion: The analytical sensitivity and accuracy of this assay were adequate for characterization of talinolol in rat plasma and the assay has been applied successfully to the in vivo kinetic study of talinolol in rats. After talinolol (10 mg kg-1) was given orally, the maximum concentration and the AUC0-∞ were 341.8 ± 99.4 ng ml-1 and 976.26 ± 173.37 ng h ml-1, respectively. The oral bioavailability was approximately 52.14 ± 9.26{\%}. Conclusion: The advantages of our method are a small sample volume (200 μl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.",
author = "Pathak, {Shriram M.} and Musmade, {Prashant B.} and Bhat, {Krishnamurthy M.} and Nayanabhirama Udupa",
year = "2010",
month = "1",
doi = "10.4155/bio.09.162",
language = "English",
volume = "2",
pages = "95--104",
journal = "Bioanalysis",
issn = "1757-6180",
publisher = "Future Science",
number = "1",

}

Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. / Pathak, Shriram M.; Musmade, Prashant B.; Bhat, Krishnamurthy M.; Udupa, Nayanabhirama.

In: Bioanalysis, Vol. 2, No. 1, 01.2010, p. 95-104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study

AU - Pathak, Shriram M.

AU - Musmade, Prashant B.

AU - Bhat, Krishnamurthy M.

AU - Udupa, Nayanabhirama

PY - 2010/1

Y1 - 2010/1

N2 - Background: A simple HPLC-UV method with a high reproducibility and sensitivity for the determination of talinolol in rat plasma was developed in this study. Method: After liquid-liquid extraction, the compounds were separated on a Vydac® C18 monomeric column (250 × - 4.6 mm inner diameter × - 5-μm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min-1. Escitalopram was used as an internal standard. The chromatographic peak-area ratio, based on UV absorbency at 245 nm, was used for quantitative analysis. Results: Calibration standards with concentrations over the range of 10-1000 ng ml-1 were validated for routine sample analysis to support pharmacokinetic studies with talinolol in rats. The intra- and inter-day precision studies showed good reproducibility with coefficients of variation of less than 11.49%. The developed method is simpler and more sensitive than previously reported methods. Discussion: The analytical sensitivity and accuracy of this assay were adequate for characterization of talinolol in rat plasma and the assay has been applied successfully to the in vivo kinetic study of talinolol in rats. After talinolol (10 mg kg-1) was given orally, the maximum concentration and the AUC0-∞ were 341.8 ± 99.4 ng ml-1 and 976.26 ± 173.37 ng h ml-1, respectively. The oral bioavailability was approximately 52.14 ± 9.26%. Conclusion: The advantages of our method are a small sample volume (200 μl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.

AB - Background: A simple HPLC-UV method with a high reproducibility and sensitivity for the determination of talinolol in rat plasma was developed in this study. Method: After liquid-liquid extraction, the compounds were separated on a Vydac® C18 monomeric column (250 × - 4.6 mm inner diameter × - 5-μm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min-1. Escitalopram was used as an internal standard. The chromatographic peak-area ratio, based on UV absorbency at 245 nm, was used for quantitative analysis. Results: Calibration standards with concentrations over the range of 10-1000 ng ml-1 were validated for routine sample analysis to support pharmacokinetic studies with talinolol in rats. The intra- and inter-day precision studies showed good reproducibility with coefficients of variation of less than 11.49%. The developed method is simpler and more sensitive than previously reported methods. Discussion: The analytical sensitivity and accuracy of this assay were adequate for characterization of talinolol in rat plasma and the assay has been applied successfully to the in vivo kinetic study of talinolol in rats. After talinolol (10 mg kg-1) was given orally, the maximum concentration and the AUC0-∞ were 341.8 ± 99.4 ng ml-1 and 976.26 ± 173.37 ng h ml-1, respectively. The oral bioavailability was approximately 52.14 ± 9.26%. Conclusion: The advantages of our method are a small sample volume (200 μl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.

UR - http://www.scopus.com/inward/record.url?scp=79953298632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953298632&partnerID=8YFLogxK

U2 - 10.4155/bio.09.162

DO - 10.4155/bio.09.162

M3 - Article

VL - 2

SP - 95

EP - 104

JO - Bioanalysis

JF - Bioanalysis

SN - 1757-6180

IS - 1

ER -